With the end of the COVID-19 public health emergency this spring, state Medicaid programs will begin to unwind their pandemic-related continuous coverage requirements. Milliman was commissioned by Karuna Therapeutics to evaluate how eligibility redeterminations might impact people living with serious mental illness during this coverage transition. This white paper focuses on strategies states can take, covering the following topics:  

• Medicaid’s role in coverage of individuals with mental illness
• Forthcoming Medicaid eligibility changes
• Potential factors that may contribute to loss of Medicaid Coverage 
• Implications of coverage loss
• State options to address these challenges

This report was commissioned by Karuna Therapeutics.